Slojab
10月前
Hey, maybe this will generate a trade. Maybe even TWO!
Item 8.01. Other Events
On August 7, Raphael Pharmaceutical Inc. (the “Company” or “Raphael”) completed its product development and is ready to launch its proprietary natural formula under the “RaphaWell“ Brand for rheumatoid arthritis (“RA”) support in the United States. This follows the successful completion of a proof-of-concept clinical trial (the “Study”), conducted under IRB approval and in full compliance with FDA regulations, including participants with severe RA, as previously disclosed on a Form 8-K on December 30, 2024. The Company intends to engage with a manufacturer in the United States to scale production.
The finalized “RaphaWell” product, will be sold as a standalone clinically tested dietary supplement targeting the growing wellness market. The “RaphaWell” product is 100% natural, plant-based, and was associated with no reported side effects during the Study, addressing a significant unmet need in RA symptom management.
Raphael’s “RaphaWell” formula has undergone clinical testing, which we believe sets it apart in both credibility and efficacy from other products in the market. As previously disclosed in the Company’s Current Report on Form 8-K, filed on December 30, 2024, the Study results showed an improvement in health-related parameters, as evaluated through questionnaires. For example, pain levels dropped from 75% participants reporting a negative result to 50% in week 8 and morning stiffness showed a notable reduction from 75% participants reporting such symptom at baseline to 41.67% at week 8.
We believe that Raphael’s “RaphaWell” formula holds strong commercial potential and first-mover advantage. Detailed study data will be available to consumers via QR code on the product packaging
AveragePenny
1年前
$RAPH Raphael Pharmaceutical Announces Positive Proof-of-Concept Clinical Study Results for the Company’s Cannabinoid-Based Formula for the Treatment of Rheumatoid Arthritis
https://www.globenewswire.com/news-release/2025/01/07/3005316/0/en/Raphael-Pharmaceutical-Announces-Positive-Proof-of-Concept-Clinical-Study-Results-for-the-Company-s-Cannabinoid-Based-Formula-for-the-Treatment-of-Rheumatoid-Arthritis.html
* Patients in Study Reported Lower Pain Levels, Better Sleep Quality, and Improved Wellbeing
* Disease Activity Score Decreased by 19.2%, Reflecting a Shift in Disease Activity from High to Moderate
* More than 80% of the Study’s Participants Expressed a Desire to Continue Using Product
NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Raphael Pharmaceutical Inc. (“Raphael Pharmaceutical” or the “Company”) (OTCQB: RAPH), a clinical-stage biotechnology company advancing a novel cannabinoid-based research platform, today announced positive proof-of-concept clinical study results for the Company’s cannabinoid-based formula for the management of rheumatoid arthritis (“RA”). Citruslabs, a leading contract research organization, successfully completed this proof-of-concept clinical study in the United States under Institutional Review Board (“IRB”) approval and in compliance with U.S. Food and Drug Administration (“FDA”) regulations.
Shlomo Pilo, Chairman and CEO of Raphael Pharmaceutical, commented, “The results of our proof-of-concept clinical study are very promising and underscore the potential of our formula to improve quality of life for those suffering from rheumatoid arthritis. We intend to build on this study to create a new, improved, and cost-effective treatment option for members of the large and growing rheumatoid arthritis patient population. Our go-forward pathways include, among other options, potentially partnering with a larger global biopharma company through licensing to develop a patentable drug delivery format for our formula and to advance the manufacturing, marketing and distribution of the final product. Beyond rheumatoid arthritis, we believe that our highly purified cannabinoid-based technology platform may have broader applications to other chronic conditions linked to inflammation, such as autoimmune disease and chronic lung inflammation. We intend to advance our research in these areas as well.”
Key Findings of the Proof-of-Concept Clinical Study
The single-group clinical trial evaluated the effects of Raphael Pharmaceutical’s highly purified cannabinoid-based formula on RA and involved 12 adult participants, each of whom used 0.5 mL of the formula daily over an eight-week period. The study results demonstrate promising efficacy, with significant improvements observed in critical health outcomes, including pain levels, sleep quality, and overall well-being. These benefits became evident as early as Week 4 and were sustained through the end of the trial. The study’s key findings:
Reduction in Disease Activity Score (“DAS28”): DAS28, a comprehensive metric assessing RA disease activity, declined by 19.2%, reflecting a shift in participants from high to moderate disease activity. DAS28 is a widely used measure of RA disease activity that combines the number of tender and swollen joints, levels of inflammation, and the patient's self-assessed health. A lower DAS28 score indicates reduced disease activity, and achieving low scores is a key goal in RA management. Of note, among the data:
Participants in remission increased from 0% at baseline to 16.67% by Week 8.
Low disease activity prevalence rose from 8.33% to 16.67%.
High disease activity prevalence decreased from 66.67% at baseline to 41.67%.
Improved Symptom Reporting:
Pain-related symptoms improved significantly, with participants reporting a reduction in negative pain outcomes from 75% at baseline to 50% by Week 8.
Morning stiffness also showed notable improvement, decreasing from 75% at baseline to 41.67% at Week 8.
Patient Satisfaction and Feedback:
83.33% of participants expressed a desire to continue using the product.
91.67% indicated they would recommend the formula to others living with RA.
Biomarker Analysis:
Although blood biomarker analysis did not reveal statistically significant changes, the overall findings emphasize the clinical potential of Raphael Pharmaceutical’s formula.
This study reinforces the Company’s extensive preclinical research, which suggests that Raphael Pharmaceutical’s formula effectively reduces key parameters of rheumatoid arthritis—thereby demonstrating potential to slow the progression of RA by acting as an anti-inflammatory agent.
Raphael Pharmaceutical utilizes a highly purified cannabinoid formulation derived from select non-psychoactive strains of cannabis with excellent anti-inflammatory potential. The formulation is designed to interact and communicate with the endocannabinoid system in the human body, activating cannabinoid receptors expressed by immune cells.
The Company intends to protect its intellectual property and highly purified cannabinoid formulation with a registered patent.
StockRocket
13年前
From and older PR: Easy Energy, Inc. Announces Purchase Orders for Company's Battery-Free Cell Phone Charger the YoGen Totaling $700,000 in Gross Sales Revenue
CEO Plans World-Wide Marketing and Sales Program
Purchaser/Reseller Buys One Million Restricted Common Stock Shares Directly From the Company
LAS VEGAS, Sept. 10 /PR Newswire-First Call/ -- Easy Energy, Inc. (OTC Bulletin Board: ESYE) announced that on August 31, 2009 the Company signed purchase orders with a purchaser/reseller based in the U.S., and with the Company's distributor in the UK and Ireland, representing a large order of the Company's YoGen cell phone charger device. Gross sales revenue for these transactions total $700,000. See Company website: www.easy-energy.biz
"This is the launch of our world-wide marketing vision for the Company. We are very pleased with our immediate success and we look forward to executing our world-wide marketing and sales program. We intend to reach many markets in the U.S. and in Europe and across the globe through traditional electronics distribution channels, and through our relationships with various emergency governmental agencies and international foundations and a broad range of large and small retail centers, purchaser/resellers, brokers and others," stated Guy Ofir, Chief Executive Officer, Easy Energy, Inc.
"We, at Fame, Inc., are early purchaser/resellers of the YoGen cell phone charger device, because we think the YoGen and other products soon to come to the market by Easy Energy will revolutionize how we use many portable electronic devices including cell phones, laptop computers, digital cameras, camcorders and other electronic devices around the world. We believe in the vision and business model of the Company's CEO, Guy Ofir, which is why in addition to purchasing YoGen device units, we (my husband and I) entered into a stock purchase agreement directly with the Company for 1 million restricted common stock shares for a purchase price of .065/share," stated Alison E. Morrison, President of Fame, Inc. based in Williamsburg, Virginia.
About Easy Energy, Inc.
Easy Energy, Inc. (OTC BB: ESYE) is the sole owner of the YoGen(R) product suite of compact man-powered generators, which are designed to provide full recharging as an innovative and effective solution for cell phones and laptop computers and other portable electronics devices when conventional energy sources are not readily available. The YoGen(R), a slim, pocket-sized charger for small devices such as cell phones, GPS, iPODs, etc., which is operated by a convenient pull-cord, is the first product from the Easy Energy line to make its debut in the very near future. The YoGen Max(TM), a compact, fold-up foot-driven charger for laptop computer sized devices, which also includes its own battery pack, is scheduled to begin production in the near future. The chargers have advanced the user friendliness and economics of this technology to the point at which they become eminently practical and desirable as a means to fill a void in an almost limitless market. The company is headquartered in Las Vegas, Nevada. Fame, Inc., the reseller of the YoGen has corporate offices in Williamsburg, Virginia. For more information on our company and innovative YoGen(R) product suite, please visit our corporate website at: http://www.easy-energy.biz
Safe Harbor Statement
This press release contains certain forward-looking statements. Forward-looking statements may include our statements regarding our goals, beliefs, strategies, objectives, plans, including product and service developments, future financial conditions, results or projections or current expectations. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause actual results to be materially different from those contemplated by the forward-looking statements. Further information on potential factors that could affect our business is described under the heading "Risks Related to Our Business" in Part I, Item 1, "Description of Business" of our Annual Report on Form 10-KSB for the fiscal year ended December 31, 2007 and in our registration statement on Form S-1 no 333-150468, which was declared effective on October 31, 2008. Except as otherwise required by law, Easy Energy, Inc. undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
Contact:
Easy Energy, Inc.
1-888-230-3837
info@easy-energy.biz
SOURCE Easy Energy, Inc.
RELATED LINKS
www.easy-energy.biz
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Renee
12年前
kingpindg
12年前
DTGoody
13年前
メールアドレスで登録
